News
MEDP
596.03
-0.89%
-5.35
Weekly Report: what happened at MEDP last week (0720-0724)?
Weekly Report · 10h ago
Medpace (MEDP) Stock May Be Below Fair Value On Raised Guidance
Simply Wall St · 1d ago
Medpace: Cancellations Are Normalizing
Seeking Alpha · 2d ago
Medpace Holdings Is Maintained at Outperform by Mizuho
Dow Jones · 3d ago
Medpace Holdings Price Target Raised to $665.00/Share From $586.00 by Mizuho
Dow Jones · 3d ago
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665
Benzinga · 3d ago
Medpace Holdings Price Target Raised to $600.00/Share From $400.00 by BMO Capital
Dow Jones · 3d ago
Medpace Holdings Is Maintained at Market Perform by BMO Capital
Dow Jones · 3d ago
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600
Benzinga · 3d ago
Medpace Holdings Is Maintained at Hold by Truist Securities
Dow Jones · 3d ago
Medpace Holdings Price Target Raised to $609.00/Share From $462.00 by Truist Securities
Dow Jones · 3d ago
Truist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $609
Benzinga · 3d ago
Medpace Holdings Is Maintained at Hold by TD Cowen
Dow Jones · 3d ago
Medpace Holdings Price Target Raised to $492.00/Share From $419.00 by TD Cowen
Dow Jones · 3d ago
Medpace Holdings Is Maintained at Outperform by RBC Capital
Dow Jones · 3d ago
Medpace Holdings Price Target Raised to $692.00/Share From $484.00 by RBC Capital
Dow Jones · 3d ago
RBC Capital Maintains Outperform on Medpace Holdings, Raises Price Target to $692
Benzinga · 3d ago
Financials, tech and healthcare lead list of overbought large caps
Seeking Alpha · 3d ago
Medpace price target raised to $692 from $484 at RBC Capital
TipRanks · 3d ago
Medpace price target raised to $665 from $586 at Mizuho
TipRanks · 3d ago
More
Webull provides a variety of real-time MEDP stock news. You can receive the latest news about Medpace Holdings through multiple platforms. This information may help you make smarter investment decisions.
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.